Structure

InChI Key HDRXZJPWHTXQRI-BHDTVMLSSA-N
Smile COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl
InChI
InChI=1S/C22H26N2O4S.ClH/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3;/h5-12,20-21H,13-14H2,1-4H3;1H/t20-,21+;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H27ClN2O4S
Molecular Weight 450.99
AlogP 3.37
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 6.0
Polar Surface Area 59.08
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 29.0

Pharmacology

Action Mechanism of Action Reference
BLOCKER Voltage-gated L-type calcium channel blocker DailyMed Wikipedia Wikipedia Wikipedia Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Heart Failure 3 D006333 ClinicalTrials
Fissure in Ano 3 D005401 ClinicalTrials
Skin Diseases 1 D012871 ClinicalTrials
HIV Infections 1 D015658 ClinicalTrials
Constipation 1 D003248 ClinicalTrials
Colorectal Neoplasms 0 D015179 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
15.42
Cardiac disorders
11.3
Nervous system disorders
8.3
Injury, poisoning and procedural complications
7.69
Vascular disorders
7.43
Psychiatric disorders
6.68
Respiratory, thoracic and mediastinal disorders
6.63
Skin and subcutaneous tissue disorders
6.14
Gastrointestinal disorders
5.89
Investigations
5.32
Musculoskeletal and connective tissue disorders
3.76
Immune system disorders
3.09
Metabolism and nutrition disorders
2.85

Cross References

Resources Reference
ChEBI 645509
ChEMBL CHEMBL1697
EPA CompTox DTXSID8040147
FDA SRS OLH94387TE
Guide to Pharmacology 2298
KEGG C06958
PubChem 62920
SureChEMBL SCHEMBL20394103
ZINC ZINC00621893